Streetbeat News

Regulatory

GM

General Motors will conduct a business update on November 29 following the ratification of new labor agreements in the United States and Canada, as reported by Reuters citing the automaker.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 1:56 pm

BIDU

FXI

SPY

Baidu's CEO anticipates that U.S. sanctions will affect China's AI development in the long term. During a conference call, the CEO mentioned that Baidu is actively looking for alternatives to mitigate the impact of these sanctions.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 1:41 pm

NAOV

NanoVibronix, Inc. (NASDAQ:NAOV) has regained compliance with Nasdaq's listing requirements, specifically the minimum stockholders' equity requirement of $2.5 million. The notice received on November 20, 2023, confirms that the company has met all criteria for continued listing on The Nasdaq Capital Market, closing the previously disclosed listing matter.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 1:34 pm

JAGX

Napo Pharmaceuticals, part of Jaguar Health, Inc. (NASDAQ:JAGX), has announced that top line data from its Phase 3 OnTarget trial for crofelemer, a drug for preventing diarrhea in cancer patients, is forthcoming. The trial results are still blinded to the company and key personnel. The trial's abstract has been accepted for presentation at the San Antonio Breast Cancer Symposium in December 2023. Crofelemer is a plant-based drug approved under FDA botanical guidance, and the trial aims to address the unmet need for treatment of chemotherapy-induced overactive bowel (CIOB).

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 1:33 pm

ABVC

ABVC BioPharma has been granted a U.S. patent for PDC-1421, a treatment for ADHD. The patent application number is 17/120,965. This development could potentially enhance ABVC's intellectual property portfolio and provide a competitive edge in the ADHD treatment market.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 1:32 pm

WAVD

WaveDancer, Inc. (NASDAQ:WAVD) has regained compliance with NASDAQ's listing requirements after previously failing to meet the minimum bid price and stockholders' equity standards. The company achieved compliance through a reverse stock split and by increasing its stockholders' equity above the required threshold. NASDAQ will monitor WaveDancer for one year, and the upcoming merger with Firefly Neuroscience, Inc. is expected to further impact compliance in Q1 2024.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 1:24 pm

AVGO

NVDA

VMW

Broadcom Inc (AVGO) and VMware, Inc (VMW) have received all necessary regulatory approvals to close their merger deal, including from China. Despite this, both stocks traded lower in the premarket. The deal is expected to close on November 22, 2023. Broadcom has previously faced concerns over U.S. AI technology embargoes on China, which could affect a third of its revenue from China. Nvidia Corp (NVDA) was also mentioned in relation to U.S. plans to halt shipments of advanced AI chips to China.

Portfolio Pulse from Anusuya Lahiri

November 21, 2023 | 1:21 pm

ORTX

The US FDA has decided not to schedule an advisory committee meeting for Orchard Therapeutics' Biologics License Application for OTL-200, intended to treat Metachromatic Leukodystrophy, according to a recent SEC filing.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 1:13 pm

INFN

Infinera (NASDAQ:INFN) has been awarded a California Competes grant valued at up to $14 million to expand and modernize its U.S.-based production of next-generation semiconductors. The grant, part of the CHIPS Act initiative, will support Infinera's domestic manufacturing of indium phosphide-based compound semiconductor and monolithic photonic integrated circuit technologies, enhancing America's economic and national security in semiconductor innovation and supply chain resilience.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 1:07 pm

PLSE

Pulse Biosciences has submitted a 510(k) application to the US FDA for its CellFX nsPFA Percutaneous Electrode, a device that could potentially enhance the company's product offerings in the medical device market.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 1:04 pm